Inherited mutations in CFTR and personalised cystic fibrosis therapy Flashcards Preview

Advanced Topics in Neuroscience 2 > Inherited mutations in CFTR and personalised cystic fibrosis therapy > Flashcards

Flashcards in Inherited mutations in CFTR and personalised cystic fibrosis therapy Deck (42)
Loading flashcards...
1
Q

When was cystic fibrosis first described?

A

in 1930s

2
Q

What does the name cystic fibrosis refer to ?

A

refers to scarring and cysts in the pancreas

3
Q

How is cystic fibrosis often first detected?

A

by presence of salty skin/sweat due to increase in ionic content of sweat

4
Q

What tissues are affects in CF?

A

many tissues are affected and mainly secretory epithelia and exocrine glands

5
Q

What is the major problem with CF?

A

major problem with the lungs: regular infection, breathing difficulties- mainly only the lung infections are treated
- symptoms treated, not the underlying cause

6
Q

What type of disorder is CF?

A

it is a recessive genetic disorder

- it is a more prevalent type of recessive genetic disorder

7
Q

When was the CFTR gene discovered?

A

identified in 1980s

8
Q

How many caucasians carry a defective allele for CFTR and how many are affected?

A

1 in 25 caucasians have defective allele and 1 in 3000-4000 are affected

9
Q

What does the CFTR gene encode?

A

it encodes a membrane protein of the ABC transporter family - homologous to other members of ABC

  • nucleotide gated chloride channel, ATP hydrolysed during activation cycles - during gating cycles
  • activity is dependent upon phosphorylation by PKA
10
Q

How many different mutations have been identified in CF and what is a common mutation?

A

over 1000 different ones

- about 70% (90% in US) have the delta F508 mutation = phenylalanine deletion

11
Q

What does the CFTR channel look like ?

A

made up of a single peptide with 2 homologous domains

  • predominantly phosphorylated following activity of protein kinase A
  • phosphorylation of the R domain causes enhanced activity of the anion pore
12
Q

What are normal airways like ?

A

requires a balance between sodium and chloride ions to get correct height of pericilliary liquid
- height/volume of pericilliary liquid between the surface of epithelial cells
has to be a certain height to allow cilia to beat to remove mucus
height is determined by homeostasis of water and sodium and chloride ions

13
Q

What are the airways like in betaENaC transgenic mice/CF?

A

Transgenic mice have an overly active ENaC to induce symptoms
in CF it is caused by a decrease in CL- channel activity which alters the balance
cilia cant move as well
GAGs, chemokines and growth factors are not gotten rid of which causes infections
CF patients have a loss of sodium and chloride balance due to a lack of cl efflux due to loss of function mutations in CFTR

14
Q

What are they trying to do to improve treatments for CF?

A

try to develop taylor-made treatments for each individual based upon their mutation

15
Q

What are class 1 mutations ?

A

CFTR is not fully synthesised (e/g nonsense)

  • due to nucleus function
  • produces a truncated protein because the mRNA produced contains a nonsense mutation
16
Q

What are class 2 mutations ?

A

CFTR is retained in the ER (e.g. deltaf508)

- ends up being degraded by ERAD

17
Q

What are class 3,4,5 and 6 mutations?

A

present in plasma membrane but dont function properly

  • class 3: impaired CFTR activation
  • class 4: reduced chloride conductance- reduced open probability- may only be open for a very short period of time
  • class 5: CFTR synthesis partly defective- fewer channels at the plasma membrane
  • class 6: altered ion permeation - very rarely occurs , opens normally but few ions flow through per cycle
18
Q

What is important about the inheritance of alleles in CF?

A

inheritance of any 2 mutant alleles causes CF-dont have to be the same alleles they can be 2 different types of mutations
e.g deltaF508/deltaF508 or deltaF508/G551D

19
Q

What are the therapeutic strategies for CF?

A

ANTIBIOTICS- mainly just focusing on treating symptoms - treating infections that occur due to improper removal of substances from the lungs
GENE THERPAY- starting to try and treat the underlying causes of the disorder- idea of delivering a working copy of the gene to the lungs

20
Q

Why is it difficult to deliver a working copy of the gene to the lungs?

A

due to the thick layer of mucus in the CF it is difficult to administer exogeneous substance

21
Q

What is pharmacotherapy treatment ?

A

it is when the function of the mutant CFTR is tried to be restored
- targetting a specific type of mutation and try to make it work more like WT

22
Q

What are the altered signialling pathway that could be targeted in CF treatment?

A

try to increase cAMP

- cAMP can stimulate ion channels so increasing it should increase activity of channels via phosphorylation of PKA

23
Q

Why would it be beneficial to inhibit ENaC?

A

to try and compensate for loss of Cl- channel activity

24
Q

What other channels could they try and activate?

A

try and activate other cl- channels

25
Q

What % of activity do they need to be able to reach to restore lung function ?

A

> 20% CFTR ACTIVITY relative to normal is though to be enough to restore lung function

26
Q

What are CFTR potentiators?

A

drugs that stimulate CFTR activity- basically CFTR agonists

  • stimulate ion channel activity but it only does this in certain circumstances- cant treat class 2 because these channels are not in the plasma membrane
  • so only works for mutations that dont affect trafficking and synthesis of the protein
27
Q

What is an example of a CFTR potentiator?

A

IVACAFTOR (VX-770)
- drug now used clinically
works with type 3 (low basal activity), type 4 (smaller currrents) and type 5 (fewer channels in the membrane)
but this is only about 5% of CF patients
due to the low number of patients that this benefits, pharma companiesdont want to invest

28
Q

Where are many of the mutations ?

A

many mutations in the nucleotide binding domain so this may affect binding of ATP and hydrolysis of ATP

29
Q

What have electrophysiology recordings shown about CFTR mutations ?

A

CFTR mutations reduce channel activity- however IVACAFTOR is able to increase activity of mutant channels to level equivalent to WT behaviour

30
Q

What are CFTR correctors?

A

treatment of type 2 mutations which is most patients
also known as pharmacoloogical chaperones - somehow correct the shape, synthesis or trafficking of the molecules to the plasma membrane
- improves maturation and export of the mutant CFTR from the ER

31
Q

How are CFTR correctors thought to work ?

A

thought to work by allosteric stabilisation or by blocking degradation
- many appear to be allosteric modulators which bind to the protein and stabilise the shape to enable protein to pass through quality control and then reach the plasma membrane

32
Q

What did VX-809 do ?

A

increased CFTR maturation and chloride secretion in cultured F508 delta-HBE

  • on SDS-PAGE F508 delta migrates further because it has a lower molecular weight therefore mature protein has a higher molecular weight
  • VX809 increases the amount o f mature glycosylated protein which increases the amount of cl-channels present in the cells
33
Q

What doesn’t F508 do ?

A

doesn’t go to the golgi complex where a lot of the post translational modifications occur

34
Q

What does phosphorylation of CFTR do ?

A

it increases cl- channel activity

35
Q

What are type 1 mutations ?

A

nonsense, frameshift, splicing errors- minority of cases
5-10% of CF cases
they introduce premature stop codon and produce truncated protein

36
Q

What do amino glycoside antibiotics do ?

A

e.g. gentamicin
interfere with mRNA translation and cause errors in amino acid incoorporaton or peptide termination
- has an unusual side effect in ribosomes- can miss out stop codons an carry on reading the rest of the sequence

37
Q

What is PTC124 (Ataluren) used for ?

A

used in other disorders and can be used to treat any nonsense mutation disorder
-skips over the stop codon- as its concentration increases it causes the production of full length CFTR and improves lung function- less coughs per hour

38
Q

What treatment could be useful for type 3 mutants?

A

increasing cAMP levels
- one study did this by disrupting CFTR-NHERF2-LPA2 complex
- cftr is present in the plasma membrane with there scaffold proteins(nherf2) and LPA2(GPCR)
LPA2 is coupled to Gi and therefore activation during lung inflammation leads to less cAMP
want to disrupt the interaction of CFTR with NHEFR2 and LPA2 so there is less association - not use therapeutically yet

39
Q

What LPA2 drug was tested and what occurred?

A

CO-068 was incubated and it increased CFTR function by preventing LPA2 reducing adenyl cyclase activity
- they proved this worked by applying a CFTR inhibitor

40
Q

What other CL- channels could be activated to try and improve function ?

A

other epithelia cl- channels:

  • clc-2 (lubiprostone) used in ibs
  • calcium-activated chloride chanel (TMEM16A)- could be activated by stimulating intracellular calcium agents such as p2y agonists to increase calcium levels
41
Q

What do small molecule activators of tmem16a do ?

A

stimulate epithelial Chloride secretion and intestinal contraction

42
Q

What is Eact and T16Ainh and what did they do with them?

A

Eact= TMEM16A acitivator
T16Ainh= TMEM16A inhibitor
looked at fluid secretion in cultured bronchiolar epithelial cells
- secretion can be inhibited by T16Ainh therefore indicatingg that TMEM16A channels are important in this process